Everything below concerns Lyophilisation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-28. Numbers and descriptions here follow the published literature rather than marketing material.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
| Property | Value | Notes |
|---|---|---|
| Molecular formula (free base) | C187H291N45O59 | Approximate; salt and hydrate forms differ |
| Molecular weight | ~4113.6 Da | Varies with counterion and hydration |
| Appearance | White to off-white powder | Lyophilized research material |
| Solubility class | Freely soluble in water | As formulated; native peptide less stable near neutral pH |
| Typical storage | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
=== Chemicals === E-cigarette components include a mouthpiece, a cartridge (liquid storage area), a heating element or atomizer, a microprocessor, a battery, and some of them have a LED light at the tip. They are disposable or reusable devices. Disposable ones are not rechargeable and typically cannot be refilled with a liquid. There is a diverse range of disposable and reusable devices, resulting in broad variations in their structure and their performance. Since many devices include interchangeable components, users have the ability to alter the nature of the inhaled vapor. For the majority of e-cigarettes, many aspects are similar to their traditional counterparts, such as giving nicotine to the user. The use of an e-cigarette simulates the action of smoking, with a vapor that somewhat resembles cigarette smoke. E-cigarettes do not involve tobacco combustion, and they do not produce vapor between puffs. They do not produce sidestream smoke or sidestream vapor. Vapor production basically entails preprocessing, vapor generation, and postprocessing. First, the e-cigarette is activated by pressing a button, or other devices switch on by an airflow sensor or other type of trigger sensor. Then, power is released to an LED, other sensors, and other parts of the device, and to a heating element or other kind of vapor generator. Subsequently, the e-liquid flows by capillary action to the heating element or other devices to the e-cigarette vapor generator. Second, the e-cigarette vapor processing entails vapor generation.
de novo synthesis The assembly of a synthetic nucleic acid sequence from free nucleotides without relying on an existing template strand, i.e. de novo, by any of a variety of laboratory methods. De novo synthesis makes it theoretically possible to construct completely artificial molecules with no naturally occurring equivalent, and no restrictions on size or sequence. It is performed routinely in the commercial production of customized, made-to-order oligonucleotide sequences such as primers.
== Reception and legacy == In August 1961, at the International Congress of Biochemistry in Moscow, Nirenberg presented the poly-U experiments – first to a small group, but then at Francis Crick's urging, again to about a thousand attendees. The work was very enthusiastically received, and Nirenberg became famous overnight. The paper describing the work was published the same month. The experiment ushered in a furious race to fully crack the genetic code. Nirenberg's main competition was the esteemed biochemist Severo Ochoa. Dr. Ochoa and Dr. Arthur Kornberg shared the 1959 Nobel Prize in Physiology or Medicine for their previous "discovery of the mechanisms in the biological synthesis of ribonucleic acid and deoxyribonucleic acid." However, many colleagues at the National Institutes of Health (NIH) supported Nirenberg, aware that it may lead to the first Nobel Prize by an intramural NIH scientist. DeWitt Stetten Jr., the NIH director who first hired Nirenberg, called this period of collaboration "NIH's finest hour." Indeed, "for their interpretation of the genetic code and its function in protein synthesis," Marshall W. Nirenberg, Robert W. Holley, and Har Gobind Khorana were awarded the 1968 Nobel Prize in Physiology or Medicine. Working independently, Dr. Holley (Cornell University) had discovered the exact chemical structure of transfer-RNA, and Dr. Khorana (University of Wisconsin in Madison) had mastered the synthesis of nucleic acids. Dr. Nirenberg showed - excluding nonsense codons - every combination of a triplet (i.e.
Sources: en.wikipedia.org
In science and technology, an arbitrary unit (abbreviated arb. unit, see below) or procedure defined unit (p.d.u.) is a relative unit of measurement to show the ratio of amount of substance, intensity, or other quantities, to a predetermined reference measurement. The reference measurement is typically defined by the local laboratories or dependent on individual measurement apparatus. It is therefore impossible to compare "1 arb. unit" by one measurer and "1000 arb. unit" by another measurer without detailed prior knowledge on how the respective "arbitrary units" were defined; thus, the unit is sometimes called an unknown unit. The unit only serves to compare multiple measurements performed in similar environment, since the ratio between the measurement and the reference is a consistent and dimensionless quantity independent of what actual units are used. Units of such kind are commonly used in fields such as physiology to indicate substance concentration, and spectroscopy to express spectral intensity. When the reference measurement is precisely defined and internationally agreed upon, arbitrary units can also be a unit capable of public comparison. One example of a publicly defined arbitrary unit is the WHO International Unit.
=== Synthetic ionophores === Many synthetic ionophores are based on crown ethers, cryptands, and calixarenes. Pyrazole-pyridine and bis-pyrazole derivatives have also been synthesized. These synthetic species are often macrocyclic. Some synthetic agents are not macrocyclic, e.g. carbonyl cyanide-p-trifluoromethoxyphenylhydrazone. Even simple organic compounds, such as phenols, exhibit ionophoric properties. The majority of synthetic receptors used in the carrier-based anion-selective electrodes employ transition elements or metalloids as anion carriers, although simple organic urea- and thiourea-based receptors are known.
==== Depression and suicidality ==== Isotretinoin is the only non-psychiatric drug on the FDA's top 10 list of drugs associated with depression and is also within the top 10 for suicide attempts. A black box warning for suicide, depression, and psychosis has been present on isotretinoin's packaging in the United States since 2005. In March 2018, European Medicines Agency issued a warning on a possible risk of neuropsychiatric disorders (such as depression, anxiety, and mood changes) following the use of oral retinoids, including isotretinoin, though the limitations of the available data did not allow them to establish whether this risk was due to the use of retinoids. A Swedish retrospective cohort study with 5756 patients showed a significantly increased risk of attempted suicides from 6 months after the treatment to around 2 years after the treatment. In 2012, a systematic review covering all articles in the literature related to isotretinoin, depression, and suicide, as well as articles related to class effect, dose-response, and biological plausibility found that the literature reviewed was consistent with an association of isotretinoin administration and depression and with suicide in a subgroup of vulnerable individuals. Following this systematic review, in a 2014 review a group of Australian dermatologists and psychiatrists collaborated on a set of recommendations for safe prescribing of isotretinoin. However, whether isotretinoin use is causally associated with mental illness remains controversial.
== Neuroendocrine tumors (209–209) == 209 Neuroendocrine tumors 209.0 Malignant carcinoid tumors of the small intestine 209.1 Malignant carcinoid tumors of the appendix, large intestine, and rectum 209.2 Malignant carcinoid tumors of other and unspecified sites 209.3 Malignant poorly differentiated neuroendocrine carcinoma 209.4 Benign carcinoid tumors of the small intestine 209.5 Benign carcinoid tumors of the appendix, large intestine, and rectum 209.6 Benign carcinoid tumors of other and unspecified sites
Sources: en.wikipedia.org
Fimbrian legions: 86 BC – 66 BC, Lucius Valerius Flaccus. These two legions fought in the Mithridatic Wars. Legio I Germanica (Germanic): 48 BC – AD 70 (Revolt of the Batavi), Julius Caesar (emblem: bull) Legio II Sabina (Sabine): 43 BC – 4th century AD, early name of the Legio II Augusta, Octavian Legio III Cyrenaica (from Cyrene): probably c. 36 BC to (at least) the 5th century, Mark Antony Legio III Gallica (Gallic): around 49 BC to at least early 4th century, Julius Caesar (emblem: bull) Legio IV Macedonica (Macedonian): 48 BC – AD 70 (renamed by Vespasian), Julius Caesar (emblem: bull, capricorn) Legio IV Scythica (from Scythia): c.
=== Top-down methods === Top-down methods adopt some 'force' (e. g. mechanical force, laser) to break bulk materials into nanoparticles. A popular method involves mechanical break apart bulk materials into nanomaterials is 'ball milling'. Besides that, nanoparticles can also be made by laser ablation which apply short pulse lasers (e. g. femtosecond laser) to ablate a target (solid).
The new 24th district, centered on Dallas Fort Worth International Airport in the heart of the Dallas–Fort Worth metroplex, encompasses the suburbs north of Fort Worth and Dallas, including Grapevine, Bedford, North Richland Hills and Southlake in northeast Tarrant County, and the wealthy Park Cities north of downtown Dallas, as well as the neighboring Knox Park and Lower Greenville neighborhoods and most of north Dallas (including Preston Hollow) in Dallas itself and the Dallas County suburbs of Farmers Branch and Coppell. Due to redistricting, the district has two incumbents, Republican Beth Van Duyne, who was re-elected with 60.3% of the vote in 2024, and Democrat Julie Johnson, who was elected with 61.9% of the vote in 2024 from the old 32nd District. Donald Trump won 57.1% of the vote in this affluent district, which also gave Ted Cruz 54.6% of the vote that same year against Democrat Colin Allred, whom Johnson succeeded in Congress. Johnson has since decided to seek reelection in the newly redrawn 33rd district (see below).
Sources: en.wikipedia.org
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.
Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.
No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.
Ice formation concentrates solutes and can mechanically stress the peptide or damage the delivery device. Thawing afterwards may leave aggregates that are not visible to the eye. Refrigeration keeps the solution above its freezing point while slowing chemical degradation.